For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction.
The aim of this study was to evaluate the efficacy and safety of oral sildenafil to treat erectile dysfunction ( ED ) in chronic renal failure in patients on hemodialysis ( HD ) . A double-blind , r and omized , placebo-controlled study of oral sildenafil ( 50 mg ) administered as required in HD patients with ED was design ed . Patients on HD for at least 6 mo and who had a stable relationship with a female sexual partner were included . Patients older than 70 yr with penile anatomic abnormalities , cirrhosis , diabetes , angina , severe anemia , and those who were on nitrate treatment or with a recent history of stroke or myocardial infa rct ion were not included . The International Index of Erectile Dysfunction ( IIEF ) was employed to evaluate ED and treatment response . Forty-one patients were evaluated ( 21 received placebo , and 20 sildenafil ) . Baseline clinical and demographic parameters were similar in both groups . Sildenafil was associated with improvement in the score of all questions and domains of the IIEF , except those related to sexual desire . Using the erectile function domain to evaluate primary efficacy , improvement was observed in 85 % of the sildenafil patients compared with 9.5 % of placebo patients . Sildenafil use result ed in normal EF scores in 35 % of sildenafil patients . Sildenafil was well tolerated . Headaches and flushing occurred in both groups . Dyspepsia was reported by two patients in the sildenafil group . In conclusion , oral sildenafil seems to be an effective and safe treatment for ED in selected patients with chronic renal failure on hemodialysis
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .